Reduction of COVID-19 Incidence and Nonpharmacologic Interventions: Analysis Using a US County–Level Policy Data Set is a research paper published in Journal of Medical Internet Research (2020). On theSindex it has a DataRank of 0. It has been cited 35 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NINDS NIH HHS
Grant: F31 NS105161
NIGMS NIH HHS
Grant: T32 GM007753
NIMH NIH HHS
Grant: T32 MH020017
FWCI
0.85
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia
Additional file 1 of Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia
Additional file of Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia
Additional file of Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia
Additional file 1 of Systematic review of empiric studies on lockdowns, workplace closures, and other non-pharmaceutical interventions in non-healthcare workplaces during the initial year of the COVID-19 pandemic: benefits and selected unintended consequences
Additional file 1 of Systematic review of empiric studies on lockdowns, workplace closures, and other non-pharmaceutical interventions in non-healthcare workplaces during the initial year of the COVID-19 pandemic: benefits and selected unintended consequences